[1]袁建伟,杨劼,贺小红,等.乳腺癌18F-FDG PET/CT和3.0T MRI联合显像评分与Ki-67表达水平的相关性分析[J].国际放射医学核医学杂志,2013,37(2):84-87.[doi:10.3760/cma.j.issn.1673-4114.2013.02.006]
　YUAN Jian-wei,YANG Jie,HE Xiao-hong,et al.Correlation between combined imaging modalities of 18F-FDG PET/CT and 3.0T MRI and expression of Ki-67 in breast cancer[J].International Journal of Radiation Medicine and Nuclear Medicine,2013,37(2):84-87.[doi:10.3760/cma.j.issn.1673-4114.2013.02.006]
点击复制

乳腺癌18F-FDG PET/CT和3.0T MRI联合显像评分与Ki-67表达水平的相关性分析(/HTML)
分享到：

《国际放射医学核医学杂志》[ISSN:1673-4114/CN:12-1381/R]

卷:
37
期数:
2013年第2期
页码:
84-87
栏目:
论著
出版日期:
2013-03-25

文章信息/Info

Title:
Correlation between combined imaging modalities of 18F-FDG PET/CT and 3.0T MRI and expression of Ki-67 in breast cancer
作者:
袁建伟1;  杨劼2;  贺小红3;  张培培4;  肖菊梅1;  王颖1
1. 佛山市第一人民医院核医学科, 佛山, 528000;
2. 佛山市第一人民医院胸外科, 佛山, 528000;
3. 佛山市第一人民医院影像科, 佛山, 528000;
4. 佛山市第一人民医院神经外科, 佛山, 528000
Author(s):
YUAN Jian-wei1;  YANG Jie2;  HE Xiao-hong3;  ZHANG Pei-pei4;  XIAO Ju-mei1;  WANG Ying1
Department of Nuclear Medicine, the First People’s Hospital of Foshan, Foshan 528000, China
关键词:
乳腺肿瘤; 增殖细胞核抗原; 正电子发射断层显像术; 体层摄影术; X线计算机; 磁共振成像
Keywords:
Breast neoplasms; Proliferating cell nuclear antigen; Positron-emission tomography; Tomography; X-ray computed; Magnetic resonance imaging
DOI:
10.3760/cma.j.issn.1673-4114.2013.02.006
摘要:
目的 探讨18F-FDG PET/CT和3.0T MRI联合显像评分与Ki-67(一种增殖细胞核抗原)表达水平的相关性。方法 18例经病理确诊的原发性乳腺癌患者术前行18F-FDG PET/CT和3.0TMRI联合显像,对显像结果进行评分并与Ki-67的表达水平进行相关性分析。联合显像和术后病理标本的免疫组化检测在一周内完成。结果 ①乳腺癌最大标准化摄取值与Ki-67的表达水平呈正相关(r=0.473,P<0.05);②PET/CT和3.0T MRI联合显像评分与Ki-67的表达水平呈明显正相关(r=0.674,P<0.01)。结论 18F-FDG PET/CT和3.0T MRI联合显像在乳腺癌的预后判断中可能具有重要的潜在价值。
Abstract:
Objective To explore the correlation between combined imaging modalities of 18F-FDG PET/CT and 3.0T MRI and expression of Ki-67 (proliferating cell nuclear antigen) in breast cancer.Methods A retrospective study was carried out in eighteen patients with pathologically confirmed primary breast cancer,who underwent both 18F-FDG PET/CT and 3.0T MRI examinations before operation.The interval between immunohistochemisty and combined imaging examinations was not more than one week after operation.The correlations between maximum standardized uptake value (SUVmax) as well as the score of combined imaging modalities and the expression level of Ki-67 were analyzed.Results ①Apositive correlation between SUVmax and expression level of Ki-67 was demonstrated in breast cancer lesions(r=0.473,P<0.05).②A significantly positive correlation between the score of combined imaging modalities and the expression level of Ki-67 was also noted (r=0.674,P<0.01).Conclusion Tumor proliferation can be reflected by the combined imaging modalities of 18F-FDG PET/CT and 3.0T MRI,indicating a potential role in predicting prognosis of breast cancer.

参考文献/References:

[1] Kuhl CK,Mielcarek P,Klaschik S,et al.Dynamic breast M R imag-ing:are signal intensity time course data useful for differential diagnosis of enhancing lesion?.Radiology,1999,211(1):101-110.
[2] de Azambuja E,Cardoso F,de Castro G Jr,et al.Ki-67 as prognos-tic marker in early breast cancer:a meta-analysis of published studies involving 12155 patients.Br J Cancer,2007,96(10):1504-1513.
[3] Viale G,Regan MM,Mastropasqua MG,et al.Predictive value oftumor Ki-67 expression in two randomized trials of adjuvant chemoendocrine therapy for node-negative breast cancer.J Natl Cancer Inst,2008,100(3):207-212.
[4] Avril N,Menzel M,Dose J,et al.Glucose metabolism of breast can-cer assessed by 18F-FDG PET:histologic and immunohistochemi-cal tissue analysis.J Nucl Med,2001,42(1):9-16.
[5] Eberlein TJ.Current management of carcinoma of the breast.Ann Surg,1994,220(2):121-136.
[6] 贾臻,章英剑,胡夕春.乳腺癌ER、PR及Her-2的表达状态与18F-FDG摄取的研究进展.中国癌症杂志,2011,21(10):807-811.
[7] 徐慧,贾文霄,周梅.乳腺癌动态增强MRI表现与病理、分子预后指标的相关性分析.中国医学影像杂志,2011,19(2):121-128.
[8] 王美芹,董珉,徐新宇.乳腺癌MRI表现与免疫组化相关性的初步研究.医学影像学杂志,2010,20(8):1130-1133.
[9] 舒虹,梅金红,谭亚敏,等.乳腺癌MRI形态学表现与ER、PR、CerbB-2及Ki-67相关性研究.实用临床医学,2011,12(8):97-100.

相似文献/References:

[1]杨雷,袁卫红,王家平,等.99Tcm-MIBI显像与钼靶X线对乳腺癌诊断的比较研究[J].国际放射医学核医学杂志,2016,40(2):111.[doi:10.3760/cma.j.issn.1673-4114.2016.02.005]
　Yang Lei,Yuan Weihong,Wang Jiaping,et al.Diagnostic value of technetium 99Tcm sestamibi and X-ray mammography in breast cancer: a comparison study[J].International Journal of Radiation Medicine and Nuclear Medicine,2016,40(2):111.[doi:10.3760/cma.j.issn.1673-4114.2016.02.005]
[2]马乐,张万春,李晓敏.乳腺癌前哨淋巴结核素显像新进展[J].国际放射医学核医学杂志,2016,40(2):145.[doi:10.3760/cma.j.issn.1673-4114.2016.02.012]
　Ma Le,Zhang Wanchun,Li Xiaomin.Evolution of radionuclide imaging of sentinel node lymphscintigraphy in breast cancer[J].International Journal of Radiation Medicine and Nuclear Medicine,2016,40(2):145.[doi:10.3760/cma.j.issn.1673-4114.2016.02.012]
[3]储小飞,赵舒怡,樊赛军.肿瘤干细胞与辐射抗性的研究进展[J].国际放射医学核医学杂志,2015,39(5):431.[doi:10. 3760 / cma. j. issn. 1673-4114. 2015. 05. 019]
　chu xiaofei,zhao shuyi,fan saijun..advance progress of cancer stem cells and radioresistance[J].International Journal of Radiation Medicine and Nuclear Medicine,2015,39(2):431.[doi:10. 3760 / cma. j. issn. 1673-4114. 2015. 05. 019]
[4]陈伟君,孙达.99Tcm-MIBI显像在乳腺癌新辅助化疗中的应用价值[J].国际放射医学核医学杂志,2015,39(6):487.[doi:10.3760/cma.j.issn.1673-4114.2015.06.011]
　Chen Weijun,Sun Da.Clinical value of 99Tcm-MIBI imaging in neoadjuvant chemotherapy of breast cancer[J].International Journal of Radiation Medicine and Nuclear Medicine,2015,39(2):487.[doi:10.3760/cma.j.issn.1673-4114.2015.06.011]
[5]胡鸿,唐刚华,聂大红.乳腺癌分子显像研究进展[J].国际放射医学核医学杂志,2015,39(1):91.[doi:10.3760/cma.j.issn.1673-4114.2015.01.019]
　Hu Hong,Tang Ganghua,Nie Dahong.Progress on molecular imaging of breast cancer[J].International Journal of Radiation Medicine and Nuclear Medicine,2015,39(2):91.[doi:10.3760/cma.j.issn.1673-4114.2015.01.019]
[6]黄娟,颜剑豪,梁联保,等.注射钆剂后弥散加权成像对乳腺肿瘤诊断的影响[J].国际放射医学核医学杂志,2015,39(4):287.[doi:10.3760/cma.j.issn.1673-4114.2015.04.003]
　Huang Juan,Yan Jianhao,Liang Lianbao,et al.Evaluation of the diffusion-weighted imaging after contrast for the characterization of breast tumors[J].International Journal of Radiation Medicine and Nuclear Medicine,2015,39(2):287.[doi:10.3760/cma.j.issn.1673-4114.2015.04.003]
[7]李雯,冯彦林.18F-FDG PET/CT评估三阴性乳腺癌新辅助化疗疗效的研究进展[J].国际放射医学核医学杂志,2014,38(3):197.[doi:10.3760/cma.j.issn.1673-4114.2014.03.013]
　Li Wen,Feng Yanlin.Advances of assessment with 18F-FDG PET/CT in triple-negative breast cancer during neoadjuvant chemotherapy[J].International Journal of Radiation Medicine and Nuclear Medicine,2014,38(2):197.[doi:10.3760/cma.j.issn.1673-4114.2014.03.013]
[8]殷丽娜,张旭霞,张俊香,等.Wnt/β-catenin信号通路——乳腺癌的潜在治疗靶点[J].国际放射医学核医学杂志,2014,38(4):252.[doi:10.3760/cma.j.issn.1673-4114.2014.04.011]
　Yin Lina,Zhang Xuxia,Zhang Junxiang,et al.The Wnt/β-catenin signaling pathway-a potential therapeutic target of breast cancer[J].International Journal of Radiation Medicine and Nuclear Medicine,2014,38(2):252.[doi:10.3760/cma.j.issn.1673-4114.2014.04.011]
[9]刘超,邓智勇,刘鹏杰,等.89SrCL2与唑来膦酸联合治疗乳腺癌转移性骨肿瘤的疗效分析[J].国际放射医学核医学杂志,2014,38(5):300.[doi:10.3760/cma.j.issn.1673-4114.2014.05.006]
　Liu Chao,Deng Zhi-yong,Liu Peng-jie,et al.Analysis on the curative effect of combination therapy with zoledronic acid and 89SrCL2 on bone tumor with breast cancer metastasis[J].International Journal of Radiation Medicine and Nuclear Medicine,2014,38(2):300.[doi:10.3760/cma.j.issn.1673-4114.2014.05.006]
[10]胡梦裳,章斌.PET/CT显像在乳腺癌疗效评价及预后中的作用[J].国际放射医学核医学杂志,2014,38(5):332.[doi:10.3760/cma.j.issn.1673-4114.2014.05.013]
　Hu Meng-shang,Zhang Bin.The role of PET/CT imaging in the evaluation of the efficacy and prognosis of breast cancer[J].International Journal of Radiation Medicine and Nuclear Medicine,2014,38(2):332.[doi:10.3760/cma.j.issn.1673-4114.2014.05.013]

备注/Memo

备注/Memo:
收稿日期:2012-11-08。
基金项目:佛山市医学类科技攻关项目(项目编号:200908066);佛山市卫生局科研项目(项目编号:2010056)
通讯作者:袁建伟,Email:yjwei214@hotmail.com
更新日期/Last Update: 1900-01-01